Clobeskine ointment 0.05% tube 25 g

Active ingredient: clobetasol;

1 g of the drug contains 0.5 mg of micronized clobetasol propionate;

Excipients: propylene glycol, sorbitan sesquioleate, white soft paraffin.

Hypersensitivity to any component of the drug. Untreated skin infections, rosacea, acne vulgaris, itching without inflammation, perianal and genital itching, perioral dermatitis. The drug is not intended for the treatment of dermatoses in children under 1 year of age, including dermatitis and diaper rash.

The ointment is particularly suitable for the treatment of skin lesions accompanied by dryness, lichenification or peeling.

Apply the ointment gently in a thin layer, covering all affected areas of the skin, 1 or 2 times a day until clinical symptoms improve (if there is a good response to treatment, improvement is achieved in a few days), then reduce the frequency of application or change to a less potent preparation. After each application of the ointment, wait some time until it is completely absorbed before applying an emollient.

Pregnant women

Only if the expected benefit to the mother outweighs the risk to the fetus.

Children

The drug is contraindicated for the treatment of dermatoses, including dermatitis, in children under 1 year of age.

Drivers

No effect.

Symptoms: With normal use, Clobetasol may be absorbed in quantities sufficient to produce systemic effects. The likelihood of acute overdose is very small, but in case of chronic overdose or improper use, signs of hypercorticism may occur.

Treatment. In case of overdose, the drug should be gradually discontinued by reducing the frequency of ointment application or replacing it with a less potent GCS, taking into account the risk of GCS insufficiency.

Further treatment should be carried out according to the patient’s clinical condition or according to national guidelines for the treatment of poisoning (if available).

On the part of the immune system: local hypersensitivity.

Skin and subcutaneous tissue disorders: itching, local burning sensation/pain in the skin, local skin atrophy, atrophic skin streaks, telangiectasias, skin thinning, skin wrinkling, skin dryness, pigmentation changes, hypertrichosis, exacerbation of the main symptoms, allergic contact dermatitis/dermatitis, pustular psoriasis, erythema, rash, urticaria, acne.

It has been shown that co-administration with drugs that can inhibit CYP3A4 (e.g. ritonavir, itraconazole) inhibits the metabolism of corticosteroids and may cause systemic effects.

Store in the original packaging at a temperature not exceeding 25 °C.

Keep out of reach of children.

Shelf life – 2 years.